Model of CE of remdesivir for Covid-19_27Aug20.xlsx (971.01 kB)
MOSAIC: A model to assess the cost-effectiveness of remdesivir for admitted COVID-19 patients in South Africa
dataset
posted on 2020-09-14, 14:22 authored by Susan ClearySusan Cleary, Cynthia Tamandjou TchuemCynthia Tamandjou Tchuem, geetesh solankigeetesh solanki, Tommy WilkinsonTommy Wilkinson| MODEL STRATEGIES |
| This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death |
| Four competing strategies are modelled: |
| 1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir |
| 2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day |
| 3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day |
| 4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/day |
| MODEL OUTCOMES |
| Cost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspective |
| Health outcomes: mean DALYs and deaths per admitted patient |
| Other outcomes: mean ICU days and inpatient days per admitted patient |
| Budget impact: mean costs (or savings) associated with intervention implementation |
